ImClone Narrows Focus To VEGFR2 In Breast Cancer Phase III Trial
This article was originally published in The Pink Sheet Daily
Pivotal study is expected this year with the compound in gastric tumors as well.
You may also be interested in...
Five new antibodies in cancer clinical trials sweeten takeover pot for BMS.
Bristol-Myers Squibb/ImClone/MerckKGaA’s cetuximab significantly prolongs survival in the first-line treatment of NCSLC.
In a creative deal that echoes the strategic tie-up last year between Infinity and Mundipharma, Italian giant Chiesi Farmaceutici is buying a majority stake in Cornerstone Therapeutics, which gets $15.5 million along with U.S. rights for 10 years to Chiesi's marketed lung surfactant Curosurf